Compare CMU & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CMU | LUNG |
|---|---|---|
| Founded | 1987 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Industrial Specialties |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 90.0M | 72.2M |
| IPO Year | N/A | 2020 |
| Metric | CMU | LUNG |
|---|---|---|
| Price | $3.55 | $1.46 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $6.81 |
| AVG Volume (30 Days) | 67.2K | ★ 374.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 4.08% | N/A |
| EPS Growth | N/A | ★ 10.00 |
| EPS | ★ 0.07 | N/A |
| Revenue | N/A | ★ $83,789,000.00 |
| Revenue This Year | N/A | $9.21 |
| Revenue Next Year | N/A | $5.03 |
| P/E Ratio | $51.57 | ★ N/A |
| Revenue Growth | N/A | ★ 22.01 |
| 52 Week Low | $3.18 | $1.31 |
| 52 Week High | $3.64 | $8.10 |
| Indicator | CMU | LUNG |
|---|---|---|
| Relative Strength Index (RSI) | 45.80 | 39.58 |
| Support Level | $3.48 | $1.34 |
| Resistance Level | $3.61 | $1.93 |
| Average True Range (ATR) | 0.04 | 0.11 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 27.27 | 24.14 |
Mfs High Yield Municipal Trust is a United States-based diversified, closed-end management investment company. Its investment objective is to seek high current income exempt from federal income tax. The fund invests a majority of its net assets, including assets attributable to preferred shares and borrowings for investment purposes, in tax-exempt bonds and tax-exempt notes. The company invest various top Healthcare companies, Airport, Universities (Secondary Schools), Universities (Dormitories), and many more, out of maximum revenue is gained from Healthcare Hospitals and Long Term Care.
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.